Cargando…
Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non‐small cell lung cancer
Immune checkpoint inhibitors (ICIs) have shown promising efficacy in the treatment of non‐small cell lung cancer (NSCLC). Sex‐associated dimorphism in immune system response is acknowledged, but the effect of patients’ sex on efficacy of ICIs as treatment in NSCLC still remains controversial. The pr...
Autores principales: | Wang, Chengdi, Qiao, Wenliang, Jiang, Yuting, Zhu, Min, Shao, Jun, Ren, Pengwei, Liu, Dan, Li, Weimin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639192/ https://www.ncbi.nlm.nih.gov/pubmed/31165589 http://dx.doi.org/10.1002/cam4.2280 |
Ejemplares similares
-
Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer
por: Shao, Jun, et al.
Publicado: (2020) -
The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis
por: Wang, Chengdi, et al.
Publicado: (2019) -
High‐dose corticosteroid use and risk of hospitalization for infection in patients treated with immune checkpoint inhibitors––A nationwide register‐based cohort study
por: Sørup, Signe, et al.
Publicado: (2021) -
Bempegaldesleukin (BEMPEG; NKTR‐214) efficacy as a single agent and in combination with checkpoint‐inhibitor therapy in mouse models of osteosarcoma
por: Hennessy, Marlene, et al.
Publicado: (2020) -
Cancer burden attributable to human papillomavirus infection by sex, cancer site, age, and geographical area in China
por: Duan, Rufei, et al.
Publicado: (2019)